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Summary
Objective: To evaluate the prognostic utility of serum COMP level measured with a new sandwich ELISA, by correlating COMP level with
outcome measures of osteoarthritis (OA) progression.
Design: Patients (N=48) had symptomatic primary knee OA of Kellgren–Lawrence (K–L) grade I–III and met ACR criteria. These patients
were evaluated prospectively as part of a double-blind drug trial of 3 years’ duration and represented the placebo arm of the study. Serum
COMP levels were measured by sandwich ELISA with monoclonal antibodies 16-F12 and 17-C10 at baseline and at study end and levels
were correlated with changes in (1) joint space width (JSW), (2) K–L grade, (3) Lequesne, and (4) WOMAC indices, over 3 years.
Results: The change in JSW over 3 years, summed for both knees, correlated positively with serum COMP level at baseline as well as at
study end. Patients were sorted by level of progression based upon a change in K–L grade summed for both knees over 3 years; patients
who progressed by two K–L grades were shown to have had significantly higher COMP levels at baseline as well as at study end. Baseline
and study end COMP levels did not correlate with the change of Lequesne or WOMAC indices. Baseline COMP levels correlated strongly
with end serum COMP levels.
Conclusion: Serum COMP has the potential to be a prognostic marker of disease progression. High COMP levels, persisting over the 3-year
study period in the patients with radiographic progression, indicated differences in disease activity detectable throughout the entire follow-up
interval. © 2002 OsteoArthritis Research Society International. Published by Elsevier Science Ltd. All rights reserved.
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Cartilage oligomeric matrix protein (COMP) is a member of
a thrombospondin family of extracellular proteins that was
initially isolated from cartilage1. COMP is a calcium-binding
protein2 of high molecular weight (>500 kDa), composed of
five identical subunits3. The carboxy-terminal globular
domain of native COMP binds to collagens I, II, and IX4–6.
Mutations in domains of type 3 calcium-binding repeats or
the carboxy-terminal globular domain, that affect binding of
calcium or collagen type IX, respectively, cause two types
of skeletal dysplasias, pseudoachondroplasia and some
forms of multiple epiphyseal dysplasia5,6.
Osteoarthritis (OA) is a common disease causing pain
and disability in a significant proportion of the adult popu-
lation7. It is characterized by the progressive destruction of
articular cartilage and concomitant changes in subchondral
bone8. A diagnosis of knee OA, traditionally based upon
weight bearing radiographs and pain, is usually made by707the time joint tissue degeneration is already advanced.
Therefore, much attention has been focused on developing
assays for ‘molecular markers’, namely cartilage-derived
macromolecules or their fragments whose release into the
circulation from the joint may reflect disturbances in joint
tissue turnover9,10. A particular need has been to develop
markers to sensitively predict initiation and progression of
OA.
Besides COMP, hyaluronan (HA) is the only other sero-
logic marker reported to have predictive value for the
progression of knee OA11. Baseline serum HA levels were
significantly increased over 5 years, when progressors
were compared with non-progressors (P<0.05). The
association of HA level to OA progression was even more
significant (P<0.001) when end serum HA levels were
examined.
The previously published studies evaluating serum
COMP as a potential prognostic marker of OA progression
utilized polyclonal antibodies12–16. We have developed a
panel of monoclonal antibodies (mAb) to human COMP17.
Our previous study of serum COMP, using mAb 17-C10 in
an inhibition ELISA, distinguished groups of OA-affected
and unaffected subjects, and also subgroups sorted by
severity of OA and number of large joints involved18,
suggesting that COMP level could be used as a surrogate
measure of disease status. Our current aim was to evaluate
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PATIENTS
Selected patients (N=48) had symptomatic primary knee
OA of Kellgren–Lawrence (K–L)19 grade I–III and met ACR
criteria20. These patients were evaluated prospectively as
part of a double-blind drug trial of 3 years’ duration and
represented the patients randomized to the placebo arm of
the study. In addition to placebo, these patients were
treated with paracetamol, up to 3 g daily. Patients were
predominantly female with bilateral knee OA (Table I). The
study was approved by the local research ethics com-
mittee. Fasting sera were obtained at entry and at the end
of the study, and stored at −70°C. Standing anteroposterior
weight-bearing radiographs of both knees were obtained
simultaneously with sera, and patients were interviewed to
obtain two multidimensional measures of disease severity,
the Lequesne algofunctional index (ISK)21, and the
WOMAC index22. The signal knee was defined without
knowledge of the radiographic data as the worst of the two
knees on the basis of subjective complaints and objective
clinical findings. At entry, patients were also examined by a
single rheumatologist, who clinically assessed three signs
of knee joint inflammation (tenderness, non-bony swelling,
and warmth), on which basis a determination of synovitis
was made (with synovitis defined as the presence of joint
tenderness of grade at least 1 plus swelling and/or warmth
of grade at least 1 for the same knee)23.RADIOGRAPHIC ASSESSMENT AND READING PROCEDURES
Joint space width (JSW) measurements and K–L grading
were performed on both the baseline and end radiographs
at the same time, exactly as described24, by two indepen-
dent readers blinded to the patient’s name, date, and
chronology of the radiographs.COMMERCIALLY AVAILABLE IMMUNOASSAYS
C-reactive protein (CRP) levels were measured by sand-
wich ELISA assay supplied as a kit (UBI MAGIWELL CRP
QUANTITATIVE AD-401) by UBI, Mountain View, CA.Table I
Characteristics of the 48 patients at entry in the study
Age, years, mean (range) 62.8 (48–74)
Gender, male/female, number (%) 14/34 (29%/71%)
OA duration, years, mean (S.D.) 11.1 (6.2)
BMI*, kg/m2, mean (S.D.) 26.4 (1.7)
ISK†, mean (S.D.) 8.5 (2.4)
Knee OA, unilateral/bilateral, number (%) 7/41 (15%/85%)
Kellgren–Lawrence grade‡, I/II/III, number (%) 8/22/18 (17%/46%/37%)
Knee synovitis, total/unilateral/bilateral, number (%) 32/26/6 (67%/54%/13%)
OA of other large joints (total/hip/spine/hip+spine), number (%) 15/8/6/1 (31%/17%/13%/2%)
*BMI=body mass index.
†ISK=The Index of Severity for Knee OA according to Lequesne et al.21.
‡A patient was classified according to the grade of the worst knee in cases of bilateral knee OA.COMP ELISA
COMP was analysed with a new sandwich ELISA,
employing two previously described mAbs, 16-F12 and
17-C1017, whose epitopes have been mapped to the
pentameric helical NH2-terminal domain and the EGF-like
domain of the COMP subunit, respectively (Vilim, unpub-
lished results). These mAbs did not compete for binding to
COMP antigen, when tested in steric competition exper-
iments set up in the format of antibody capture assays
(Vilim, unpublished results). MAbs were purified from
ascitic fluid by chromatography on a column of immobilized
Protein G and concentrated by ultrafiltration. MAb 17-C10
was labeled by LC-biotin using EZ-Link NHS-LC-Biotin
(Pierce) to yield a molar ratio IgG:biotin of approximately
1:50. MAb 16-F12 was used as the first (capture) mAb, and
biotinylated mAb 17-C10 was used as the second (detec-
tion) mAb in the assay. Nunc-Immuno (MaxiSorp) plates
(Nunc) were coated with 100 g/ml of mAb 16-F12 in
PBS/0.02% sodium azide, 50 l/well. Plates were covered
with sealing tape and put on an orbital shaker for 2 h and
then left standing at least overnight (up to 3 weeks) at 4°C.
Coating solution could be used repeatedly. Coated plates
were washed twice with PBS and blocked with 3% BSA/
PBS/0.02% sodium azide, [120 l/well, 2 h on the orbital
shaker and than standing overnight (or up to 1 week) at
4°C]. Blocked plates were washed twice with PBS immedi-
ately before use. COMP standard, purified as previously
described17 from human articular cartilage, was diluted to
10 g/ml with 0.05% Tween-20/10 mM EDTA/0.01%
Thiomerosal/1% BSA, aliquoted and kept frozen at −70°C.
Once thawed, this diluted standard was either used or
discarded.
Prior to ELISA, samples/standards were diluted in
0.01% BSA in PBS on low-binding Nunc MicroWell plates.
Standard was titrated from the initial concentration of
400 ng/ml to six wells (400, 200, 100, 50, 25, 12.5 ng/ml).
Serum samples were diluted 1/20. Samples and standards
were mixed and transferred (50 l from each well) onto
coated, blocked, and washed MaxiSorp plate and incu-
bated for 2 h on orbital shaker at room temperature. Plates
were washed five times with PBS and the labeled second
mAb (biotinylated 17-C10) was added (50 l/well). The
second mAb was diluted from a concentrated stock to
2 g/ml in 0.01% BSA/PBS. Plates were incubated for 2 h
on the orbital shaker at room temperature and then washed
five times with PBS. Streptavidin-horseradish peroxidase
conjugate (Amersham Pharmacia Biotech) was diluted
500× by 0.01% BSA/PBS and added at 50 l/well. Platesthe prognostic utility of serum COMP level measured with
a new sandwich ELISA, by correlating COMP level
with outcome measures of OA progression.
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temperature and then washed five times with PBS/0.05%
Tween 20. Peroxidase substrate (o-phenylenediamine plus
H2O2), 100 l/well was added for 30 min at room tempera-
ture. The production of chromophore was stopped by
addition of 50 l/well of 2 M H2SO4. Plates were read at a
wavelength of 492 nm. COMP concentrations in samples
were calculated from a standard curve and results were
expressed as equivalents of the standard human antigenic
COMP (g/ml). Samples, which fell below/above the
standard range, were measured repeatedly at lower/higher
dilution. The order of the samples was then randomized,
and the measurements repeated a second time. These two
independent measurements had to fall within the limits of
interassay variance of the assay. Each plate contained four
identical samples of ‘control’ serum that was stored in
aliquots at −70°C. Each day a fresh aliquot of the control
serum was thawed and used on each plate to calculate
intra- and interassay variance25; these were found to be
less than 8% and less than 10%, respectively. All samples
were assayed simultaneously with the same set of
reagents. Analyses were performed without knowledge
of the radiographic and clinical data.STATISTICAL METHODS
An association between continuous variables was
assessed using the Pearson test and linear regression.
Associations between continuous and qualitative variables
were evaluated by analysis of variance (ANOVA). Compari-
sons of COMP levels in two groups of patients were done
by the non-parametric Mann–Whitney test. Baseline and
end COMP levels within one group of patients were com-
pared using a paired t-test. A P-value (two-tailed) <0.05
was considered significant.Fig. 1. Correlation between baseline (a) and end (b) serum COMP
levels, and radiographic OA progression, expressed as a change
in JSW for the signal knee over 3 years. The linear regression line
is shown.Fig. 2. Correlation between baseline (a) and end (b) serum COMP
levels, and radiographic OA progression, expressed as a change
in JSW summed for both knees over 3 years. The linear regression
line is shown.Fig. 3. Baseline (a) and study end (b) serum COMP levels in
patients sorted according to severity of OA progression, expressed
as the decrease in JSW for either knee over 3 years. Horizontal
lines show mean COMP levels. Patients showing a decrease of
JSW <0.5 mm were considered to be non-progressors (N=38);
patients showing a decrease of JSW >0.5 mm were considered to
be progressors (N=10). *=P<0.05 and **=P<0.01 comparing
progressors with non-progressors (Mann–Whitney test).Results
Only age significantly affected COMP levels in this study.
Other potential confounding variables [gender, body mass
index, OA duration, CRP level at entry, K–L grade at entry,
the presence of knee synovitis at entry, the presence of OA
of other large joints at entry, and the number of large joints
(knee, hip, spine) affected at entry] were without a signifi-
cant effect. Unadjusted COMP levels are demonstrated in
the Figures, since adjusting for age did not change the
overall results.
An association between a change in JSW over 3 years
and serum COMP level was assessed. We found a signifi-
cant correlation of serum COMP level with a change in
JSW for the signal knee over 3 years. The association was
significant for COMP level at the study end (P<0.001), but
not for COMP level at baseline (Fig. 1). When summed for
both knees, a change in JSW over 3 years correlated
positively with serum COMP level at baseline (P<0.01)
as well as at study end (P<0.001) (Fig. 2). The corre-
lation remained statistically significant after adjusting
COMP levels for age.
When the threshold used to designate a patient as a
‘progressor’ was defined as a decrease in JSW over
3 years >0.5 mm for either knee, a total of 10 of the
48 patients progressed, and 38 of the patients did not
progress. Although serum COMP levels in these two
groups overlapped (Fig. 3), the mean COMP level was
higher in the progressors (Table II) and the difference inCOMP level between the two groups was significant using
a non-parametric Mann–Whitney test (P<0.05 for COMP
level at baseline and P<0.01 for COMP level at the study
end).
Patients were further sorted by level of progression
based upon a change in K–L grade over 3 years. The signal
knee showed either no change in K–L grade (group 0), or
an increase by one K–L grade (group 1). No patient
progressed more than one K–L grade, when only the signal
knee was taken into account. Although serum COMP levels
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Serum COMP levels for groups of patients by radiographic progression
Serum COMP (g/ml)
Baseline Study end
All patients (N=48)
Mean±S.D. 4.16±1.03 4.47±1.37
Median (range) 3.92 (2.2–6.3) 4.24 (1.9–8.4)
Decrease of JSW, either knee (mm) <0.5 >0.5 <0.5 >0.5
(N=38) (N=10) (N=38) (N=10)
Mean±S.D. 3.96±0.94 4.92±1.05 4.11±0.90 5.85±1.96
Median (range) 3.88 (2.2–6.3) 5.02 (3.3–6.3)* 4.16 (2.3–6.1) 6.35 (1.9–8.4)**
Increase in K–L grade, signal knee 0 1 0 1
(N=33) (N=15) (N=33) (N=15)
Mean±S.D. 3.96±1.01 4.60±0.96 4.25±1.24 4.97±1.56
Median (range) 3.88 (2.2–6.3) 4.37 (3.4–6.3)* 4.14 (1.9–7.8) 4.36 (2.3–8.4)
Increase in K–L grade, both knees† 0 2 0 2
(N=29) (N=9) (N=29) (N=9)
Mean±S.D. 3.91±0.97 5.11±1.01** 4.12±1.11 5.79±1.71**
Median (range) 3.88 (2.2–6.1) 5.32 (3.5–6.3) 4.18 (1.9–6.3) 5.04 (3.9–8.4)
Decrease of JSW, either knee: *P<0.05 and **P<0.01 compared with group <0.5 (Mann–Whitney test).
Increase in K–L grade, signal knee: *P<0.05 compared with group 0 (Mann–Whitney test).
Increase in K–L grade, both knees: **P<0.01 compared with group 0 (ANOVA, Bonferroni post test).
†Serum COMP levels in the group of ten patients who progressed by only one K–L grade were not significantly
different from levels in the group of patients who did not progress (data not shown).Fig. 4. Baseline (a) and study end (b) serum COMP levels in
patients sorted according to severity of OA progression, expressed
as the change in K–L grade for the signal knee over 3 years.
Horizontal lines show mean COMP levels. Group 0 non-
progressors (N=33); group 1 increased one K–L grade (N=15).
*=P<0.05 and ns=not significant when compared with Group 0
(Mann-Whitney test).Fig. 5. Baseline (a) and study end (b) serum COMP levels in
patients sorted according to severity of OA progression, expressed
as the change in K–L grade summed for both knees over 3 years.
Horizontal lines show mean COMP levels. Group 0 non-
progressors (N=29); group 1 increased one K–L grade (N=10);
group 2 increased two K–L grades (N=9). **=P<0.01 when
compared with Group 0; *=P<0.05 when compared with Group 1
(ANOVA and Bonferroni post test).in these two groups overlapped (Fig. 4), the mean COMP
level was higher in group 1 patients and the difference in
baseline COMP level between the two groups was signifi-
cant using a non-parametric Mann–Whitney test (P<0.05),
the difference in COMP level at the study end was not
significant. Subjects were also categorized according to the
sum of the change that occurred in K–L grade for both
knees: group 0 no change, group 1 increased one K–L
grade, group 2 increased 2 K–L grades. The mean COMP
levels in these groups differed significantly at baseline as
well as at study end (ANOVA, P<0.01 before adjusting and
P<0.05 after adjusting for age). Group 2 had higher mean
COMP levels than (1) group 0 non-progressors (P<0.01
before adjusting and P<0.05 after adjusting for age) and (2)
group 1 that progressed by one K–L grade (P<0.05, both
before and after adjusting for age) at baseline as well as at
study end (Bonferroni multiple comparisons post hoc test)(Fig. 5). Mean and median COMP levels by radiographic
progression status are summarized in Table II.
Baseline serum COMP levels correlated strongly with
study end serum COMP levels (P<0.0001) (Fig. 6). Since
two former studies12,13 have shown a correlation between
progression status and the change in serum COMP level
over time, we also evaluated our data in this manner.
Progression was defined as a change in JSW of >0.5 mm
for either knee over 3 years, or as a 2 grade increase in
K–L grade summed for both knees over 3 years. Although
we noticed an increase in serum COMP level over the
3-year follow-up period in the whole cohort (Table II), this
increase was similar for all patients. The change in COMP
(from baseline to study end) was not significantly different
in the groups separated according to progression status
using a paired t-test.
Osteoarthritis and Cartilage Vol. 10, No. 9 711Baseline and study end COMP levels did not correlate
with changes of ISK or WOMAC indices.Fig. 6. Correlation between baseline and study end serum COMP
levels. The linear regression line is shown.Discussion
We have developed a sandwich ELISA with two mono-
clonal antibodies to human COMP. The sandwich ELISA
format offers the advantage of higher specificity and sensi-
tivity over other ELISA methods of biomarker quantification.
We performed this study with the goal of relating serum
COMP levels to the progression of knee OA. We demon-
strated that baseline serum COMP levels correlated with
the magnitude of OA radiographic progression, thus serum
COMP has the potential to be a prognostic marker of
disease progression.
In previous studies, we have observed an association
between serum COMP level and knee OA disease severity
(K–L grade), serum COMP level and the number of OA
affected large joints18, and serum COMP level and syno-
vitis23. In this much smaller study we observed the same
trends, which however, did not achieve statistical signifi-
cance, we presume due to the lack of power. Age was the
only other factor that we have identified in previous studies,
whose effect on serum COMP levels remained statistically
significant even in the relatively small group analysed here.
However, adjusting COMP levels for age did not affect
conclusions reached by this study.
Several previous studies have evaluated serum COMP
and OA progression. Sharif et al.12 and Petersson et al.13
found no correlation between baseline serum COMP levels
and subsequent OA progression during 5 years of follow-up
of patients with established knee OA and during 3 years of
follow-up of patients with early knee OA, respectively. They
found, however, a significant positive correlation between
the change (the increase) in serum COMP level during the
first year12 and during the 3-year interval13 respectively,
and radiographic progression during the whole follow-up
interval. Conrozier et al.14 found a significant correlation
between baseline serum COMP levels and 1-year radio-
graphic progression of patients with established hip OA.
They found no correlation between the change in serum
COMP level over time and yearly mean narrowing of joint
space width. In agreement with the hip OA study, we
observed a similar correlation between serum COMP level
at baseline and radiographic progression in a knee OA
cohort. In contrast to the two previous studies on knee OA,
we detected no association between the change in serum
COMP level and progression status. Instead, we found that
serum COMP levels at baseline and at study end correlated
strongly, indicating that serum COMP level distinguishedprogressors from non-progressors throughout the follow-up
interval.
Although it is expressed by other tissues within a joint26,
COMP prevails in the articular cartilage and it has been
demonstrated that serum levels are representative of
cartilage catabolism10. Thus, the correlation of serum
COMP level with joint space narrowing, a radiographic
indicator of cartilage catabolism, is plausible. The recent
report that COMP is expressed by vascular smooth muscle
cells27 hampers straightforward interpretation of serum
COMP levels in the setting of joint disease. While the
potential contribution of these cells to serum COMP level is
difficult to predict, it seems reasonable to expect that
production of COMP by non-cartilaginous tissues is
responsible for a certain background or constitutive serum
level, and that pathological degradation of cartilage adds
significantly to this background level. HA is the only other
biomarker, which has been shown to predict knee OA
progression11. Like COMP, HA is not tissue specific but
serum levels increase significantly in response to activity of
pathological joints28,29. Thus, it is indeed possible for a
tissue specific process to measurably contribute to the
level of a biomarker in the circulation. In general, we found
the best correlation between COMP level and radiographic
progression when both knees were included in the
analysis. This result is expected for a marker, such as
COMP, whose potential release from all joints in the body
contributes to the serum level.
It is difficult to decide whether measurement of JSW is
superior to composite scoring systems such as K–L grading
for assessing radiographic progression of OA, thus the use
of both approaches has been recommended30. It has
became obvious recently, that precise measurement of the
interbone distance on weight-bearing anteroposterior radio-
graphs may be obscured by the fact that even relatively
minor changes in a patient’s position (usually due to
different degrees of flexion) can result in large changes in
the measured apparent joint space width. This methodo-
logical shortcoming impacts practically all longitudinal
studies, including ours, initiated prior to 1995, when the
influence of joint positioning on the standardization and
reproducibility of tibiofemoral JSW measurement on
sequential OA knee joint radiographs was published31. A
recent retrospective assessment of several former longi-
tudinal OA studies has elucidated the overall effect of lower
limb positioning on JSW measurements32,33. In total, cor-
rect alignment of the medial tibial plateau with the X-ray
beam, and standardization of knee rotation on sequential
radiographs ranged from 9 to 19% of all examined pairs of
radiographs in four retrospectively assessed cohorts of OA
patients32. Significant widening of joint space in the medial
compartment was found in 23% of all examined knees. We
are aware of this potential shortcoming, the presence of
which in our study is indicated by the fact that we recorded
widening of the knee joint space in 17 patients, (35%) out of
48 who received placebo, over the period of 3 years.
Although, hypothetically, there may be several reasons for
apparent radiographic improvement33, it is very probable
that at least some of these apparent ‘improvements’ can be
ascribed to misalignment of sequential radiographs. How-
ever, a correlation of serum COMP level with radiographic
OA progression was not based on JSW measurements
alone in this study. We also observed a correlation of serum
COMP level with K–L grade worsening. Although the K–L
grading system is considered to be relatively insensitive,
results do not depend on JSW alone, are less affected by
joint positioning and standardization of grading is based
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ment’ over the 3-year interval using the K–L grading
system. The fact that serum COMP and OA progression
are correlated on the basis of both JSW measurements and
K–L grading argues strongly, in our opinion, that this finding
is valid.
The test does not meet the criterion of discriminant
validity, as its ability to detect small changes seems to be
rather limited; however, a similar limitation could be said to
apply to the currently accepted ‘gold standard’ for OA,
namely joint radiography. Furthermore, at present, serum
COMP level cannot be used to prognosticate the course of
OA in an individual patient due to the high variability and
the overlap of COMP values in affected and unaffected
groups. However, COMP level may aid in identifying groups
of patients at risk of faster disease progression and in
differentiating groups of patients during clinical studies and
drug trials that are analysed using statistical methods.References
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